Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Intervalo de año de publicación
1.
J Clin Pharm Ther ; 38(2): 101-3, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23278401

RESUMEN

WHAT IS KNOWN AND OBJECTIVE: It is now estimated that about 5% of cetuximab-treated patients and about 3% of panitumumab-treated patients will develop grade 3-4 hypomagnesemia. The aim of this study was to assess the extent of magnesium monitoring in patients treated with epidermal growth factor receptor (EGFR)-targeting antibodies and to estimate the incidence of hypomagnesemia in these patients at our institution. METHODS: A 2-year retrospective study was carried out. At least four doses of weekly cetuximab or two doses of bi-weekly panitumumab were required for inclusion. Serum magnesium profiles were reviewed from 1 month before treatment until 3 months after treatment discontinuation, and patients with <2 determinations were excluded. RESULTS AND DISCUSSION: Two hundred and one patients received at least one dose of EGFR-targeting antibodies, but only 68 met the inclusion criteria. Seventy patients had <2 magnesium determinations. The overall hypomagnesemia was 58·82% (40 of 68 patients), with a 4·41% grade 3 hypomagnesemia (three of 68 patients). No grade 4 hypomagnesemia was detected. WHAT IS NEW AND CONCLUSION: There is a lack of magnesium monitoring in these patients. Serum magnesium determinations should be done every 4-8 weeks in patients treated with EGFR-targeting antibodies, as it is a useful surrogate marker for both toxicity and efficacy.


Asunto(s)
Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Monoclonales/efectos adversos , Receptores ErbB/antagonistas & inhibidores , Receptores ErbB/inmunología , Magnesio/sangre , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales Humanizados/administración & dosificación , Cetuximab , Femenino , Humanos , Masculino , Persona de Mediana Edad , Panitumumab , Estudios Retrospectivos
4.
Fam. aten. prim ; 9(1): 2-7, ene.-abr. 2011. ilus, tab
Artículo en Español | IBECS | ID: ibc-106460

RESUMEN

Objetivo. Identificar medicación inadecuada y fármacos necesarios no prescritos en pacientes de cuatro residencias geriátricas y cuantificar la modificación de tratamientos que realizan médicos a partir de las recomendaciones hechas por farmacéuticos. Material y métodos. Estudio cuasi experimental pre-post sin grupo control. La intervención consistió en la comunicación de prescripciones inapropiadas, basadas en los criterios STOPP-START, detectadas en los médicos responsables. Resultados. Se revisaron las historias clínicas de 121 pacientes mayores de 65 años. Ochenta y ocho pacientes (72,7%) presentaron como mínimo un criterio STOPP-START, con una media de 2 criterios por paciente. Se observó al menos una potencial prescripción inadecuada (STOPP) en 79 pacientes (65,3%) y una omisión de un tratamiento necesario (START) en 36 pacientes (29,7%). El médico aceptó como mínimo uno de los criterios detectados y modificó el tratamiento de 47 pacientes (53,4%). Se cambió el tratamiento de 33 pacientes (41,8%) siguiendo los criterios STOPP y de 20 pacientes (55,5%) según los criterios START. Conclusión. La prescripción inadecuada de fármacos y la no utilización de fármacos necesarios es un problema frecuente en geriatría (AU)


Objective. This study has aimed to determine the prevalence of inappropriate prescribing (IP) and of necessary drugs not prescribed in a geriatric population living in four assisted care nursing homes and to quantify the changes in medications made by physicians based on the recommendations made by the pharmacists. Methods. A pre-post quasi-experimental study without a control group was performed. The intervention consisted of the communication of inappropriate prescriptions based on the STOPPSTART criteria to the responsible physicians Results. The medical records of 121 patients over 65 year were reviewed. Of these, 88 patients (72.7%) had at least one STOPP-START criterion, with an average of 2 criteria per patient. At least one potential inappropriate drug (STOPP criterion) was detected in 79 patients (65.3%) and 36 patients (29.7%) were not receiving at least one drug indicated for their diseases (START criterion). The practitioners accepted at least one of the criteria detected and modified the medical prescription of 47 patients (53.4%). Treatment was modified in 33 patients (41.8%) following the STOPP criteria and 20 patients (55.5%) following the START criteria. Conclusion. Inappropriate drug prescription and the lack of using of the necessary medications is a frequent problem in older patients (AU)


Asunto(s)
Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Prescripción Inadecuada/prevención & control , Utilización de Medicamentos/normas , Enfermedad Crónica/tratamiento farmacológico , Anciano Frágil , Salud del Anciano Institucionalizado , Atención Primaria de Salud/métodos , Polifarmacia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...